文献速递血栓与止血白血病

纳武利尤单抗联合紫杉醇治疗铂耐药卵巢癌、原发性腹膜癌或输卵管癌的Ib期研究

Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
PubMed 文献 · J Clin Oncol · 2022-04-19

这项开放标签、非随机、剂量递增和扩展的Ib期研究纳入44例既往治疗过的复发性铂耐药2/3级卵巢癌患者,评估纳武利尤单抗(3或4 mg/kg每2周)联合紫杉醇(80 mg/m2,28天周期第0、7、14天)的安全性和疗效。总体客观缓解率为43.2%(95%CI 28.3-59.0),既往接受贝伐珠单抗治疗者为33.3%(95%CI 17.3-52.8),未接受贝伐珠单抗者为64.3%(95%CI 35.1-87.2),生物标志物阳性者为62%(95%CI 31.6-86.1)。结论认为该联合方案在贝伐珠单抗经治和初治患者中显示出有前景的临床活性,毒性可控。

要点

  • 纳武利尤单抗联合紫杉醇在铂耐药卵巢癌中总体客观缓解率为43.2%(95%CI 28.3-59.0)。
  • 未接受贝伐珠单抗者客观缓解率64.3%(95%CI 35.1-87.2),接受过贝伐珠单抗者为33.3%(95%CI 17.3-52.8)。
  • 生物标志物阳性者客观缓解率为62%(95%CI 31.6-86.1)。

核心结论

  • 纳武利尤单抗联合紫杉醇在贝伐珠单抗经治和初治的铂耐药卵巢癌患者中显示出有前景的临床活性,毒性可控。

研究设计与样本

  • 开放标签、非随机、剂量递增和扩展的Ib期研究,纳入44例既往治疗过的复发性铂耐药2/3级卵巢癌患者。
  • 治疗方案为静脉纳武利尤单抗(3 mg/kg或4 mg/kg每2周一次)联合紫杉醇(80 mg/m2静脉注射,28天周期第0、7、14天)。
  • 剂量递增队列纳入纳武利尤单抗3 mg/kg每2周一次(n=3)和4 mg/kg每2周一次(n=2),选择3 mg/kg进行扩展(n=39)。
  • 回顾性使用基于RNA的诊断面板检测33例患者的肿瘤微环境亚型,并与肿瘤缓解进行相关性分析。

主要发现

  • 未发生剂量限制性毒性。
  • 最常见的3/4级治疗相关不良事件为高血压(40.9%)、中性粒细胞减少(6.8%)和血小板减少(4.5%)。
  • 肺动脉高压发生率为18.2%(1-2级)。
  • 总体客观缓解率为43.2%(95%CI 28.3-59.0);既往接受贝伐珠单抗治疗者为33.3%(95%CI 17.3-52.8),未接受贝伐珠单抗者为64.3%(95%CI 35.1-87.2),生物标志物阳性者为62%(95%CI 31.6-86.1)。
  • 中位缓解持续时间为6个月(95%CI 5.4个月至不可估计)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This phase Ib study evaluated the safety and efficacy of paclitaxel plus navicixizumab, a bispecific antiangiogenic antibody to vascular endothelial growth factor and delta-like ligand 4, against platinum-resistant ovarian cancer. PATIENTS AND METHODS: This open-label, nonrandomized, dose-escalation and -expansion study included 44 patients with previously treated, recurrent, platinum-resistant grade 2/3 ovarian cancer. Treatment was intravenous navicixizumab (3 mg/kg or 4 mg/kg once every 2 weeks) plus paclitaxel (80 mg/m2 intravenously on days 0, 7, and 14 of 28-day cycles). The primary and secondary objectives were to evaluate the safety and efficacy of navicixizumab plus paclitaxel. An RNA-based diagnostic panel was retrospectively used to test the hypothesis that tumors with high angiogenesis or immune-suppressed tumor microenvironment (TME) subtypes (biomarker-positive) are more likely to respond to navicixizumab than those with immune-active/-desert TME subtypes (biomarker-negative). RNA expression was analyzed in available pretreatment tumor tissue to classify 33 patients' TME subtypes, and TME panel findings were correlated with tumor response. RESULTS: The dose-escalation cohorts enrolled patients at navicixizumab doses of 3 mg/kg once every 2 weeks (n = 3) and 4 mg/kg once every 2 weeks (n = 2); 3 mg/kg was selected for expansion (n = 39). No dose-limiting toxicities occurred. The most common grade 3/4 treatment-related adverse events were hypertension (40.9%), neutropenia (6.8%), and thrombocytopenia (4.5%). Pulmonary hypertension occurred in 18.2% (grade 1-2). The overall objective response rate was 43.2% (95% CI, 28.3 to 59.0): 33.3% (95% CI, 17.3 to 52.8) in patients previously treated with bevacizumab, 64.3% (95% CI, 35.1 to 87.2) in bevacizumab-naive patients, and 62% (95% CI, 31.6 to 86.1) in biomarker-positive patients. The median duration of response was 6 months (95% CI, 5.4 months to not estimable). CONCLUSION: Navicixizumab plus paclitaxel demonstrated promising clinical activity in bevacizumab-treated and -naive patients with platinum-resistant ovarian cancer, with manageable toxicity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fu S, Corr BR, Culm-Merdek K, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022. PMID: 35439029. doi:10.1200/JCO.21.01801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。